

Press release from Emotra AB (publ)  
Göteborg, April 28, 2015

## Bulletin from the Annual General Meeting of Emotra AB

**The Annual General Meeting of shareholders in Emotra AB took place on April 27, 2015, at which the following important resolutions were approved.**

The income statement, balance sheet and proposed appropriation of losses were adopted.

Release from liability for the Board of Directors and Chief Executive Officer.

The Board members Margit Ferm, Lars-Håkan Thorell, Claes Holmberg and Roy Jonebrant were re-elected.

Thomas Nilsson, authorised public accountant at Ernst & Young AB, was re-elected as the Company's auditor.  
Markus Hellsten, authorised public accountant at Ernst & Young AB, was re-elected as deputy auditor.

Remuneration to the board was set at SEK 120 000, to be distributed among board members as the board sees fit.

Remuneration to the auditors as per the approved invoice.

**For further information, please contact:**

*Claes Holmberg, CEO*

*Telephone: +46 708 25 45 47*

*E-mail: [claes@emotra.se](mailto:claes@emotra.se)*

---

***Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.*